Recurrence of hepatitis C infection: Where are we now?

Michael Charlton

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Key Points 1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (± ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving.

Original languageEnglish (US)
Pages (from-to)S57-S62
JournalLiver Transplantation
Issue number11 SUPPL. 2
StatePublished - Nov 2005

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation


Dive into the research topics of 'Recurrence of hepatitis C infection: Where are we now?'. Together they form a unique fingerprint.

Cite this